Key Considerations for Parkinson’s Disease Trials
Parkinson’s Disease (PD), a common neurodegenerative disorder of the central nervous system, is the subject of much R&D in the Life Sciences industry, given that there are currently no disease-modifying agents on the market. Yet, the therapeutic area poses significant challenges for clinical development— ranging from biomarker development to study design and patient recruitment and retention.
There are, however, many advances that bode well for sponsors as well as patients and caregivers. Many new biomarkers for disease progression are being explored, lessons learned from studies in Alzheimer’s Disease are proving valuable insights in study design, and creative approaches and technology are improving patient recruitment and support.
The following paper highlights such aspects of PD studies that sponsors should bear in mind as they plan their trials.